1. Resources >>
  2. Companies directory >>
  3. QED Therapeutics
QED Therapeutics

QED Therapeutics

QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Our lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. We plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.
Headquarters
Palo Alto, CA
Company size
10,001+ employees
Top employees at
QED Therapeutics
M
Mike Monteith
Senior Director, Pharmaceutical Development
Raleigh-Durham, North Carolina Area
S
Sameena Sharif
Chief Operating Officer
San Francisco Bay Area
R
Rick Panicucci
Senior Vice President CMC at QED Therapeutics and Origin Biosciences
Greater Boston Area
Y
Yining Ye
Vice President of Biostatistics and Data Management
San Francisco Bay Area
G
Gary Li
Executive Director, Translational Oncology
San Diego, California

Companies, you might be interested in:

QED Training
QED WebDevelopment
QED42 Engineering Pvt Ltd
The most popular email templates:
QED Therapeutics’s email formatsPercentage
lastName.firstNamedoe.jane@qedtx.com48%
firstNameInitiallastNameInitialjd@qedtx.com32%
lastName-firstNameInitialdoe-j@qedtx.com52%
firstName_lastNameInitialjane_d@qedtx.com66%
lastNameInitialfirstNameInitialdj@qedtx.com70%
lastNameInitial-firstNameInitiald-j@qedtx.com50%

Our Integration Partners

+ 13 more